Current treatment of low grade gliomas by Martin J. van den Bent et al.
review
  Current treatment of low grade gliomas  2231 3
Abstract  Low  grade  gliomas  affect  predominantly 
young adults,  and have a  relatively  favorable prognosis 
compared  to  grade  III  and  grade  IV  gliomas. The chal-
lenge for an optimal management of these patients is to 
find  the  balance  between  an  optimal  survival  and  the 
preservation  of  neurological  function  including  cogni-
tion.  Because  all  medical  treatments  may  induce  side 
effects,  in  young and nearly  asymptomatic patients  the 
choices  can  be  difficult.  This  review  summarizes  the 
current  strategies:  a  watch-and-wait  policy,  surgery, 
chemotherapy, and radiotherapy.
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(typical  for  oligodendroglioma),  on  the  biological  level 
mixed oligoastrocytoma do not  appear  to  reflect  a  true 
entity and its name is more indicative for the difficulties 
of  the  histological  diagnosis  of  glioma  [1]. The optimal 
treatment  of  low-grade  glioma  remains  controversial. 
Guidelines on  the early management of  young patients 




gnostic  procedures  and  treatment  as  long  as  possible, 
whereas  others  advocate  early  treatment  consisting  of 
an extensive resection with or without adjuvant therapy. 
Arguments against early treatment are derived from the 
observation  that  many  patients  remain  asymptomatic 
(apart from the seizures) for a prolonged period of time, 
and  may  deteriorate  following  treatment  [2–5].  Argu-
ments for early treatment are uncertainty about the dia-
gnosis and potentially better survival after early extensive 






The reliability of a ‘low grade glioma’ MR 
diagnosis
Although  a  typical MRI  scan with  a  nonenhancing  T2- 
hyperintense  mass  will  usually  harbor  an  LGG,  many 
exceptions exist:  reports  indicate  that up  to 30–45 % of 
nonenhancing  lesions suggestive of LGG turn out  to be 
high-grade glioma  [7]. Despite  this  fact, a biopsy  is not 
necessarily  required  in  all  cases  of  suspected  LGGs:  in 
case of a ‘watch-and-wait’ policy, adequate neuroradio-
logical  follow-up will  identify  patients with  progressive 
lesions  requiring  histological  diagnosis  and  treatment. 





Although  enhancement  is  usually  indicative  of  a  high 
grade  lesion,  LGG  (especially  oligodendroglioma)  can 
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What evidence is available to decide at what 
moment histological diagnosis should be  
obtained and treatment should be initiated?
The  only  prospective  clinical  trial  into  early  versus 
delayed  treatment  is  the  randomized  EORTC  trial  that 
showed  early  radiotherapy  improves  progression  free 
survival,  without  affecting  overall  survival  [12].  This 
study suggested that with respect to survival, the delay in 
radiotherapy does not adversely affect outcome; howe-
ver,  the  quality  of  life  and  cognition  were  not  investi-






many  years  of  follow-up  an  association  between  prior 
radiotherapy  and  cognitive  deficits  [2].  In  an  earlier 
report on  that cohort,  the  investigators had shown  that 
having a tumor, use of anticonvulsants, and radiotherapy 
with  fraction  size  exceeding  2  Gy  were  also  associated 
with cognitive deficits [15].
Can we select patients in which early diagnosis 
and treatment is indicated?
In  patients  with  focal  deficits,  raised  intracranial  pres-
sure or  tumors  showing  rapid  radiological progression, 
the  need  for  immediate  treatment  is  undisputed  [16]. 









rate  in  time,  even within  the  first  six months  is  also  of 
major  prognostic  significance  [10].  Alternative  ima-
ging techniques also hold promise. PET imaging allows 
the  identification of  tumors  in which a watch-and-wait 
policy may not be the right choice. Baseline amino acid 
uptake  on  (18)F-FET  PET  and  a  diffuse  versus  circum-
scribed  tumor pattern on MRI were  found  to be  strong 
predictors  for  the  outcome  of  patients  with  low-grade 
glioma [24]. Moreover, maps of  (18)FET uptake kinetics 














rapy  after  initial  resection.  Several  studies  have  shown 
that  residual  disease  after  surgery  is  associated  with  a 
shorter  time  to  radiological progression  [6, 25].  In  sub-
totally resected low grade glioma patients under 40 years 
of  age,  the presence of  residual disease  (≥ 1  cm  tumor) 
following surgery, initial tumor diameter over 4 cm, and 
astrocytic histology proved to be poor prognostic factors 
for  radiological  progression  [25].  Whether  this  implies 
that  in  the  presence  of  postoperative  residual  tumor 
immediate adjuvant  treatment  is  required  is however a 
different matter:  that will  also depend on  the  rationale 
for surgery. For documented growth, mass effect, or defi-
cits,  an adjuvant  treatment  should be  considered  since 
these patients have an unfavorable prognostic profile. If 
however surgery was performed in a young patient with 
seizures  only,  the  patient  can  be  followed with  further 
treatment when growth is radiologically documented.
In young patients, with a nonenhancing intracerebral 






early progression of a high-grade  tumor.  In  those cases 
that are being followed, histological confirmation can be 
postponed until  the  time  the beginning of  treatment  is 
clinically indicated (e.g., in case of radiological progres-
sion, clinical deterioration, uncontrolled seizures).
Treatments of low grade glioma
Surgery
There  are  four  objectives  when  performing  surgery  in 
suspected  LGG:  (1)  histological  confirmation  of  the 
nature of the lesion, (2) improvement of the neurological 




improve  the  neurological  condition  and  the  control  of 
seizures  [18,  26,  27]. There  are  no  randomized  trials  in 
LGG  on  the  impact  of  extent  of  resection  on  survival. 
Extensive  data  from  uncontrolled  studies  suggest  an 







by  indication)  is  unknown,  but  one  should  realize  that 
the large and excellent series from UCSF describing over 
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not  considered  ideal  candidates  for  resection, have  the 




LGG  depends  on  molecular  profile  up  (in  particular 
IDH1 mutations, MGMT promoter methylation, 1p/19q 
co-deletion,  TP53  mutations).  Specifically,  evidence  is 
accumulating  that  the  patients  with  IDH  nonmutated 
tumors  are  older,  and have  tumors  that  are  larger with 
a more  infiltrative  pattern  on MRI.  In  contrast,  tumors 
with IDH mutations may be more often localized in the 
frontal  lobe  and more  often  present  with  seizures  [28, 
29]. Such differences in molecular background will affect 
outcome,  regardless  of  treatment,  and  the  finding  of  a 
better prognosis after more extensive resection may—in 
part—be the consequence of  these baseline differences 
in molecular  profile.  It  underscores  our  limited  know-
ledge to what extent early surgery has an impact on the 
natural behavior of LGG. Regardless of these considera-
















observational  arm  received  (‘salvage’)  radiotherapy  at 
the time of recurrence, no effect on overall survival was 
seen—further supporting  the role of RT  in  this disease. 








of  neurological  function  or  improved  seizure  control 
after radiation [17, 20]. Because even after involved field 
irradiation, virtually all recurrences of LGG occur within 
the  irradiated  volume,  one might  expect  a  better  local 
control after a higher dose of  irradiation. However,  two 
large randomized multicenter trials totaling 590 patients 





The  role  of  chemotherapy  in  LGG  is  still  incompletely 




but not OS  [34]. The data  from the  randomized EORTC 




activity  of  temozolomide  and  older  studies  exploring 






studies  report  efficacy of both PCV and  temozolomide, 





[36,  40].  Astrocytoma  may  also  respond,  usually  with 








Or  at  recurrence after RT? Or  in  combination with RT? 
The tendency to use chemotherapy in lieu of RT in larger 
lesions  especially  when  sensitivity  to  chemotherapy  is 
expected  (oligodendroglioma  with  combined  1p/19q 
loss) is intuitively attractive to delay RT (and inherent late 
neurotoxicities), but good quality  clinical data  to guide 
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Conclusion
There are several treatment options for low grade glioma. 
The choice  for early  surgery  in  young and asymptoma-
tic patients is in particular driven by the hope to improve 
survival.  In particular,  smaller, well  circumscribed  lesi-
ons in noneloquent regions appear good candidates for 
early  aggressive  surgery.  If  a  conservative  watch-and-
wait policy is followed, treatment should be considered 
in case of clear documented growth without waiting for 
the  development  of  focal  deficits.  Uncontrolled  seizu-
res  are  a  reason  for  treatment,  as  seizure  control  may 




on  cognition. The  best  timing  of  chemotherapy  versus 
radiotherapy  is  still  unclear;  the  ongoing  randomized 
trials must help clarify  that.  In case of  larger  lesions or 
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